- Pattern of practice for postoperative management of endometrial cancer in Korea: a survey by the Korean Gynecologic Oncology Group and the Korean Radiation Oncology Group (KGOG 2028-KROG 2104)
-
Lee SU, Kim JY, Kim MK, Kim YS, Kim YJ, Eom KY, Wee CW
- KMID: 2552634
- J Gynecol Oncol.
- 2023 Jul;34(4):e54.
- doi: 10.3802/jgo.2023.34.e54
Objective This study aimed to investigate the current status of postoperative management of uterine endometrial cancer (EC) in Korea. Methods A mail survey was administered to members of the Korean Gynecologic Oncology Group... -
- CITED
-
- Close
- SHARE
-
- Close
- Reconstruction of the diaphragm with autologous fascia lata during cytoreduction in patients with advanced ovarian cancer
-
Kanao H, Tsumura S
- KMID: 2552635
- J Gynecol Oncol.
- 2023 Jul;34(4):e43.
- doi: 10.3802/jgo.2023.34.e43
Cytoreductive surgery for patients with advanced ovarian cancer often requires full-thickness resection of the diaphragm [1]. In most cases, the diaphragm can be closed directly; however, when the defect is... -
- CITED
-
- Close
- SHARE
-
- Close
- Parametrial involvement and decreased survival of women with FIGO stage IIIC1 cervical cancer
-
Chang H, Wang M, Liu Y, Wu Y
- KMID: 2552626
- J Gynecol Oncol.
- 2023 Jul;34(4):e46.
- doi: 10.3802/jgo.2023.34.e46
Objective To evaluate the effect of parametrial status on FIGO stage IIIC1 cervical cancer. Methods A retrospective study was conducted from June 1, 2009, to December 31, 2018.Patients with stage IIIC1 cervical cancer... -
- CITED
-
- Close
- SHARE
-
- Close
- RB1 alteration and poor prognosis in women with high-grade neuroendocrine carcinoma of the uterine cervix: a NeCTuR study
-
Legarreta AF, Salvo G, Gonzales NR, Chisholm G, Hillman RT, Frumovitz M
- KMID: 2552627
- J Gynecol Oncol.
- 2023 Jul;34(4):e50.
- doi: 10.3802/jgo.2023.34.e50
Objective To describe the gene alteration status in high-grade neuroendocrine cervical carcinoma (NECC) specimens and to explore the potential association of unique gene alterations with survival. Methods Results from tumor-based molecular testing on... -
- CITED
-
- Close
- SHARE
-
- Close
- Adjuvant pelvic radiation versus observation in intermediate-risk early-stage cervical cancer patients following primary radical surgery: a propensity score-adjusted analysis
-
Tuscharoenporn T, Muangmool T, Charoenkwan K
- KMID: 2552625
- J Gynecol Oncol.
- 2023 Jul;34(4):e42.
- doi: 10.3802/jgo.2023.34.e42
Objective To compare survival outcomes, posttreatment complications, and quality of life (QoL) of early-stage cervical cancer patients with intermediate-risk factors between those who received adjuvant pelvic radiation and those without adjuvant... -
- CITED
-
- Close
- SHARE
-
- Close
- Effects of a fertility-sparing re-treatment for recurrent atypical endometrial hyperplasia and endometrial cancer: a systematic literature review
-
Murakami I, Machida H, Morisada T, Terao Y, Tabata T, Mikami M, Hirashima Y, Kobayashi Y, Baba T, Nagase S
- KMID: 2552632
- J Gynecol Oncol.
- 2023 Jul;34(4):e49.
- doi: 10.3802/jgo.2023.34.e49
Objective To examine the effectiveness of progestin re-treatment for recurrent endometrial intraepithelial neoplasia (EIN), atypical endometrial hyperplasia (AH) and endometrial cancer (EC) following initial fertility-sparing treatment. Methods A comprehensive systematic review and meta-analysis... -
- CITED
-
- Close
- SHARE
-
- Close
- Th2 cells infiltrating high-grade serous ovarian cancer: a feature that may account for the poor prognosis
-
Su H, Jin Y, Tao C, Yang H, Yang E, Zhang WG, Feng F
- KMID: 2552631
- J Gynecol Oncol.
- 2023 Jul;34(4):e48.
- doi: 10.3802/jgo.2023.34.e48
Objective We aimed to investigate the differences of transcriptome profile between 2 groups of high-grade serous ovarian cancer (HGSOC) patients with distinct outcomes and identify potential biomarkers for recurrence. Methods RNA sequencing was... -
- CITED
-
- Close
- SHARE
-
- Close
- Effectiveness and safety of nab-paclitaxel and platinum as first-line chemotherapy for ovarian cancer: a retrospective study
-
Wang L, Li S, Zhu D, Qin Y, Wang X, Hong Z, Han Z
- KMID: 2552628
- J Gynecol Oncol.
- 2023 Jul;34(4):e44.
- doi: 10.3802/jgo.2023.34.e44
Objective To evaluate the effectiveness and safety of nab-paclitaxel plus platinum as first-line chemotherapy for ovarian cancer (OC). Methods Patients administered platinum combined with nab-paclitaxel as first-line chemotherapy for epithelial OC, fallopian tube... -
- CITED
-
- Close
- SHARE
-
- Close
- Histopathological subtyping of high-grade serous ovarian cancer using whole slide imaging
-
Miyagawa C, Nakai H, Otani T, Murakami R, Takamura S, Takaya H, Murakami K, Mandai M, Matsumura N
- KMID: 2552630
- J Gynecol Oncol.
- 2023 Jul;34(4):e47.
- doi: 10.3802/jgo.2023.34.e47
Objective We have established 4 histopathologic subtyping of high-grade serous ovarian cancer (HGSOC) and reported that the mesenchymal transition (MT) type has a worse prognosis than the other subtypes. In this... -
- CITED
-
- Close
- SHARE
-
- Close
- PTEN mutation predicts unfavorable fertility preserving treatment outcome in the young patients with endometrioid endometrial cancer and atypical hyperplasia
-
Xue Y, Dong Y, Lou Y, Lv Q, Shan W, Wang C, Chen X
- KMID: 2552633
- J Gynecol Oncol.
- 2023 Jul;34(4):e53.
- doi: 10.3802/jgo.2023.34.e53
Objective This study aimed to investigate the impact of molecular classification and PTEN, KRAS and PIK3CA gene mutation on the outcome of fertility-preserving treatment in the patients with endometrioid endometrial cancer... -
- CITED
-
- Close
- SHARE
-
- Close
- RAD51/geminin/γH2AX immunohistochemical expression predicts platinum-based chemotherapy response in ovarian high-grade serous carcinoma
-
Kim K, Kim SH, Lee JY, Kim YN, Lee ST, Park E
- KMID: 2552629
- J Gynecol Oncol.
- 2023 Jul;34(4):e45.
- doi: 10.3802/jgo.2023.34.e45
Objective The RAD51 assay is a recently developed functional assay for homologous recombination deficiency (HRD) that reflects real-time HRD status. We aimed to identify the applicability and predictive value of RAD51... -
- CITED
-
- Close
- SHARE
-
- Close
